Engflag

Erceflora

Quick links to important sections

Erceflora

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Erceflora

Property Description
Active ingredient Bacillus clausii (spores)
Form Oral suspension (vial), Hard gelatin capsule
Pharmacological class Probiotic microorganism, Supportive antidiarrheal
Common use Restoration of intestinal bacterial flora
Origin Biological (Gram-positive, spore-forming bacterium)

What Type of Medicine is Erceflora and What is its Purpose?

Erceflora is a specialized medicinal preparation classified as a probiotic microorganism agent, containing the active ingredient Bacillus clausii. It is a biological product and a single active ingredient product that belongs to the pharmacological class of probiotics. The primary goal of Erceflora is the restoration of intestinal bacterial flora when it has been disturbed, a condition commonly known as dysmicrobism or gut imbalance. This general therapeutic use relates to its role in promoting gut health. The preparation is administered via the oral route.

Composition and Formulation: The Unique Role of Bacillus clausii Spores

The sole active ingredient in Erceflora is the bacterium Bacillus clausii (INN), which is uniquely formulated as a highly resilient spore preparation. The product is most commonly available as a ready-to-use, clear oral suspension contained in mini bottles or vials, though a hard gelatin capsule form may also be available. The spore state is critical, as it provides high resistance to heat, stomach acid, and bile salts. This resilience is necessary for ensuring a sufficient quantity of the bacteria is delivered intact past the gastric environment to the lower intestine, where the active cells are needed.

The Basis of Gut Microbiota Restoration and Differentiation

The underlying basis for Erceflora's action is the successful delivery and subsequent growth of the beneficial bacteria, which actively participate in the restoration of gut microbiota composition. The resilient spores transform into vegetative cells that colonize the intestine and help compete with potentially harmful microorganisms, supporting a healthier environment. Notably, the Bacillus clausii strains used are polyantibiotic-resistant. This is a key differentiating feature, as it means the preparation can maintain its effectiveness even when a patient is undergoing a course of antibiotics, which are a frequent cause of microbial imbalance.

Regulatory References

  1. Bacillus clausii MeSH Descriptor

What side effects are possible with Erceflora?

Possible Side Effects and Safety Information

The official documentation of safety characteristics for the active ingredient, Bacillus clausii, outlines potential adverse reactions and critical constraints derived from post-marketing experience and regulatory assessments.

Documented Adverse Reactions

Adverse reactions are classified according to regulatory standards and primarily affect the skin and immune system. The official safety profile details the following:

  • Skin and Subcutaneous Tissue Disorders: Reactions associated with hypersensitivity (allergic reactions) have been reported. These include manifestations such as rash, urticaria (hives), and angioedema (swelling beneath the skin).
  • Infections and Infestations: Bacteraemia, septicaemia, or sepsis (systemic bacterial infection) are documented as serious adverse reactions. Due to the nature of their reporting, the frequency of these serious events is classified as Not known (cannot be reliably estimated from available data).

Key Safety Constraints and Special Populations

The regulatory label highlights critical limitations and population-specific warnings for safe use:

  • Route of Administration Restriction: The preparation is strictly for oral use only. Regulatory documents explicitly state that it must not be injected, as severe hypersensitivity reactions, including anaphylactic shock, have been reported following incorrect administration.
  • Population-Specific Caution: There is regulatory guidance to exercise caution or avoid use in specific vulnerable groups. This includes patients who are immunocompromised or those who are severely ill and hospitalized, such as preterm infants, due to the potential risk of systemic infection.
  • Contraindication: A known hypersensitivity to Bacillus clausii or any of the product's excipients is a formal restriction to use.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Erceflora (Bacillus clausii) provides specific information regarding overdose scenarios and mandated emergency response actions, focusing on two distinct contexts.

Documented Overdose Profile

Official product information consistently states that no cases of overdose have been reported following the oral administration of the product. This established absence of documented adverse events associated with oral over-administration means no specific signs or symptoms of toxicity are defined by regulatory bodies for this preparation when ingested in excessive quantities. In the event of accidental oral over-administration, management is limited to general symptomatic and supportive treatment, as no procedural measures are explicitly mandated in regulatory documentation.

Mandatory Emergency Actions

A critical emergency warning in the official labeling relates strictly to the route of administration. The product is for oral use only and must not be injected or administered in any other way. Urgent medical attention must be sought immediately if the product is used incorrectly (non-oral route). Regulatory documents confirm that improper use has been associated with severe, life-threatening immunological outcomes, including severe anaphylactic reactions and anaphylactic shock, which requires immediate notification of a medical professional or hospital.

Therapeutic Uses of Erceflora

What Erceflora Treats: Main Uses and Benefits

Erceflora is applied in clinical settings that involve symptoms related to systemic imbalance arising from an unbalanced intestinal bacterial flora (dysmicrobism). Its primary role is to support the restoration of gut flora, which is considered relevant for managing specific, uncomfortable symptom patterns in various clinical contexts. The clinical relevance of Bacillus clausii is recognized in its application for gastrointestinal disorders.

The medication is relevant in situations involving episodic or fluctuating manifestations, such as acute diarrhea, gastrointestinal disorders in children, and those presenting with symptoms related to systemic imbalance due to drug treatments.

Core Therapeutic Focus

The product helps address symptom clusters that may become disruptive, including the frequency of loose stools, abdominal cramping, and meteorism (bloating). In scenarios where additional symptomatic assistance is required, particularly alongside antibiotics, the product assists with maintaining functional stability.

“The primary benefit is in supporting general well-being during symptomatic phases related to an unbalanced gut environment, which may assist with easing the overall symptom burden.”

Quick Fact: Symptomatic Support for Acute Diarrhea and Abdominal Discomfort

The medication is commonly used when short-term symptomatic assistance is needed for symptoms associated with acute or disruptive episodes of diarrhea and the related physical discomfort.

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Erceflora

Regulatory documentation defines strict eligibility rules for who can and cannot use Erceflora (Bacillus clausii spores). The primary and absolute prohibition is for individuals with a known hypersensitivity (allergy) to the active substance or any of the product's excipients.

Populations Requiring Avoidance or Conditional Use

The medicine is generally not recommended for or must be avoided in certain populations with underlying clinical vulnerabilities. These include immunocompromised or severely ill patients (including critically-ill patients), where use is restricted and only permitted if the potential benefits outweigh the risks. Additionally, use should be avoided in preterm infants due to specific documented safety warnings.

Established Use and Administration Rules

Use is established and approved for adults, children, and breastfeeding infants. Some official labeling states there are no documented contraindications for use during pregnancy or lactation. A critical restriction is that the product is strictly for oral use and must not be injected or administered parenterally.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile for Erceflora (Bacillus clausii) primarily by the explicit absence of known interactions with most medicinal products. The labeling consistently states that no known interactions resulting from the simultaneous use of other drugs have been identified.

Timing-Based Administration Requirement

While systemic drug interactions are not documented, the product label mandates a specific procedural constraint when used alongside antibiotics. This is due to the potential for antibiotics to negatively affect the viability of the probiotic organism.

Interaction Type Interacting Substance Official Regulatory Requirement
Administration Constraint Antibiotics Must be administered in the interval between two subsequent administrations of the antibiotic.

This required timing separation is the only officially documented constraint related to interactions with other medicinal products. The official labeling does not contain information regarding metabolic interactions (e.g., CYP enzymes), transporter-mediated interactions, or documented interactions with food, alcohol, or herbal products.

Mechanism of Action

How Erceflora Works

Erceflora's mechanism is localized to the gastrointestinal tract and initiates with the high resistance of Bacillus clausii spores to stomach acid, allowing intact passage to the small intestine where they germinate into active vegetative cells. This proliferation directly modulates the gut microbiota by increasing the population of commensal bacteria and influencing the local microbial composition. The active strain exhibits an antagonistic interaction against undesirable microorganisms through competitive exclusion—competing for adhesion sites and nutrients—and through the production of antimicrobial substances (bacteriocins). This action decreases the quantity of bacterial toxins and modifies the influence of microbial activity on the intestinal epithelial barrier.

Furthermore, the metabolic activity of B. clausii includes the synthesis of B-group vitamins within the intestinal lumen. This biosynthesis locally modifies vitamin concentration, which influences the energy metabolism of intestinal epithelial cells. This process contributes to the structural integrity and physiological state of the epithelial barrier.

Dosage and Administration Information

Instruction Map: How to use Erceflora — Administration Guidelines

The use of Erceflora, which contains Bacillus clausii spores, involves specific instructions defining the correct route, dose, and administration conditions. The preparation is strictly for oral use only and must never be injected or administered by any other route.

Administration Scope

Instruction Category Administration Guidelines
Route of Administration Oral use only. Do not inject or administer in any other way.
Dosing Schedule (2 billion spores/unit) Adults: 2 to 3 mini bottles or capsules per day (4 to 6 billion spores).
Timing in relation to antibiotics Must be administered in the interval between doses of an antibiotic, if taken concurrently.
Preparation Requirements The oral suspension vial must be shaken well before use. It can be taken undiluted or mixed with beverages (water, milk, tea, or juice).
Age-Group Administration Rules Children/Adolescents: 1 to 2 mini bottles or capsules per day. Infants (over 1 month): 1 to 2 mini bottles per day.
Special Procedural Conditions The entire contents of an opened vial must be consumed immediately to prevent microbial contamination. Treatment duration is typically for a short course, often 5 to 14 days.

Instruction Classifications (High-Level)

Classification Description
Administration method type Oral
Frequency pattern Daily, taken in divided doses at regular intervals.
Guideline basis Governed by standardized administration protocols.
Use-context constraints Requires separation from antibiotic dosing and immediate consumption after opening.

Connection to the overall use protocol (2–4 sentences):

The use protocol is defined by the requirements for oral exclusivity and divided daily dosing to ensure proper delivery of the spores to the intestine. These administration rules govern the standardized, short-term course of the medicine across different patient populations, ensuring adherence to the intended usage principles.

Recent Clinical Evidence

The Role of Bacillus clausii in Intestinal Health

Erceflora is a probiotic containing spores of Bacillus clausii, a non-pathogenic bacterium. Due to their natural spore form, the bacteria are highly resistant to the acidic environment of the stomach and can survive transit to the intestine, where they become metabolically active. This characteristic is particularly relevant for maintaining viability during digestion.

Evidence in Clinical Trials

Clinical research, including randomized controlled trials (RCTs) in children and adults, has focused primarily on the use of Bacillus clausii as an adjunctive therapy for certain gastrointestinal conditions. Key findings from these studies include:

  • Acute Diarrhea: Studies investigating acute diarrhea in children have indicated that administration of B. clausii, alongside standard rehydration therapy, may be associated with a reduced duration of diarrhea compared to standard therapy alone. Improvements in stool consistency and frequency have also been observed within the first few days of treatment in some patient groups.
  • Antibiotic-Associated Diarrhea (AAD): Several trials support the use of the probiotic for the prevention and management of AAD in both children and adults. Bacillus clausii is notable for its natural resistance to many common antibiotics, allowing it to maintain its presence in the gut flora during concurrent antibiotic treatment.
Area of Investigation Observation in Clinical Trials
Symptom Reduction Reduction in stool frequency and duration of diarrhea
Safety Profile Generally well-tolerated; low rates of adverse events observed

Safety Considerations

Bacillus clausii is generally considered safe for use in immunocompetent individuals. However, post-marketing reports have documented rare but serious cases of bacteremia (presence of bacteria in the blood) or sepsis, primarily in severely ill or immunocompromised patients. Clinicians are advised to exercise caution when considering its use in these vulnerable populations.

Key Studies & References

  1. Effectiveness of Bacillus clausii (O/C, N/R, SIN, T) in the Prevention of Antibiotic-Associated Diarrhea and Gastrointestinal Symptoms: A Systematic Review
  2. Bacteremia Following Alkalihalobacillus clausii (Formerly Bacillus clausii) Administration in Immunosuppressed Adults: A Case Series

Frequently Asked Questions (FAQ)

Common questions about Erceflora (FAQ)

Q: Does Erceflora interact with alcohol or food?

According to the official product information, there are no known interactions documented between Erceflora and food, alcohol, or other medicinal products. Official product information notes that a timing separation from antibiotic doses is mandated when the two are used concurrently.

Q: How long does a course of treatment with Erceflora usually last?

Official regulatory labeling indicates that the duration of treatment is typically intended as a short course. Depending on the condition being treated and the patient population, this course often ranges from 5 to 14 days.

Q: Is there a risk of taking too much Erceflora?

Official regulatory safety documents report that no cases of overdose have been specifically recorded with the use of this product. As with all medicines, it is important to follow the directions given by a healthcare provider regarding use.

Q: What should I do if my symptoms don't improve after taking Erceflora?

The official product information indicates that if symptoms worsen or fail to improve, consultation with a healthcare provider is appropriate for reassessment. A healthcare professional is necessary to determine the appropriate next steps for a patient's care.

How should Erceflora be stored and disposed of?

How to Store and Dispose of Erceflora?

This section outlines the official, regulatory-based instructions for the storage and disposal of Erceflora, which contains the active ingredient Bacillus clausii (spores).

Official Storage Requirements

Requirement Specifics Mandated by Labeling
Temperature Store at a temperature not exceeding 30 C.
Environment Keep away from direct light and in a dry place.
Container Must be kept in the original container; administer the oral suspension immediately after opening the vial.
Child Safety Keep out of the sight and reach of children.

Disposal

Unused or expired medicine must be disposed of according to local government regulations (e.g., drug take-back programs). This action is required to prevent the product from entering sewage or wastewater systems, which helps maintain environmental safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Erceflora found in:

A-Z Index: